Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times
International Business Times
Business

BIZARRE: Novo nordisk cuts earning forecasts again names new ceo | Mind Blowing Facts

Copycats and rivals to Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy weigh on the Danish drugmaker's its performance (Credit: AFP)

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

The downward revisions prompted heavy selling by investors on the Copenhagen stock exchange, with Novo shares plunging 22 percent in afternoon trading.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.